PMID- 31851978
OWN - NLM
STAT- MEDLINE
DCOM- 20201201
LR  - 20201201
IS  - 1421-9735 (Electronic)
IS  - 0253-5068 (Linking)
VI  - 49
IP  - 1-2
DP  - 2020
TI  - Renal Replacement Therapy Preferences Survey: Is Allo-Hemodialysis an Acceptable 
      Option for Patient Caregivers and Health Care Professionals?
PG  - 197-201
LID - 10.1159/000504241 [doi]
AB  - End-stage kidney disease (ESKD) is a worldwide unsolved problem. Access to renal 
      replacement therapies (RRT) is still a challenge in some developed countries and 
      even more so in developing countries. Allo-hemodialysis (alloHD) is a recently 
      proposed, still hypothetical, alternative RRT where the blood of a healthy 
      subject ("buddy") flows countercurrent to the patient's blood through the 
      dialyzer. Solutes and fluid are transferred to the buddy and then cleared by 
      his/her healthy kidneys, making alloHD essentially a procedure where the buddy 
      "donates" kidney function intermittently to the patient. Its drastically reduced 
      complexity makes -alloHD particularly attractive for low-resource settings. The 
      acceptance of alloHD by patients, caregivers, and health care professionals (HCP) 
      is unknown. In this cross-sectional study, we surveyed the preferences and 
      acceptance of alloHD in 3 groups: caregivers related to ESKD patients, nonrelated 
      caregivers (nrCG), and HCP. Four areas were explored: RRT preferences, kidney 
      organ donation for transplant acceptance, -alloHD acceptance as a potential RRT, 
      and alloHD technique acceptance. Hemodialysis was the preferred form of RRT. 
      Kidney donation acceptance was similar in all groups. Intermittent kidney 
      function donation (i.e., alloHD) was mainly accepted by related and nrCG but less 
      accepted by HCP (87, 90, and 60% respectively, p < 0.01). New RRT alternatives 
      such as alloHD are expected to be better received and accepted once animal, and 
      clinical studies have demonstrated their feasibility, safety, and benefits. New 
      RRT strategies are required primarily in most vulnerable populations and should 
      be explored.
CI  - (c) 2019 S. Karger AG, Basel.
FAU - Campos, Israel
AU  - Campos I
AD  - Department of Nephrology, Hospital General "Dr. Miguel Silva", Morelia, Mexico, 
      israel.campos@gmx.com.
AD  - Department of Research and Educational, NausLife Hemodialysis Clinics, Morelia, 
      Mexico, israel.campos@gmx.com.
FAU - Arellano, Jesus
AU  - Arellano J
AD  - Department of Nephrology, Hospital General "Dr. Miguel Silva", Morelia, Mexico.
FAU - Gomez, Victor
AU  - Gomez V
AD  - Department of Nephrology, Hospital General "Dr. Miguel Silva", Morelia, Mexico.
FAU - Quiroz, Jorge
AU  - Quiroz J
AD  - Department of Nephrology, Hospital General "Dr. Miguel Silva", Morelia, Mexico.
AD  - Department of Research and Educational, NausLife Hemodialysis Clinics, Morelia, 
      Mexico.
FAU - Mariscal, Luis Alfonso
AU  - Mariscal LA
AD  - Department of Nephrology, Hospital General "Dr. Miguel Silva", Morelia, Mexico.
AD  - Department of Research and Educational, NausLife Hemodialysis Clinics, Morelia, 
      Mexico.
LA  - eng
PT  - Journal Article
DEP - 20191218
PL  - Switzerland
TA  - Blood Purif
JT  - Blood purification
JID - 8402040
SB  - IM
MH  - Adult
MH  - *Caregivers
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Kidney Failure, Chronic/*therapy
MH  - *Kidney Transplantation
MH  - Male
MH  - Middle Aged
MH  - *Renal Dialysis
MH  - *Tissue and Organ Procurement
OTO - NOTNLM
OT  - Allo-hemodialysis
OT  - Renal replacement therapy
OT  - Survey
EDAT- 2019/12/19 06:00
MHDA- 2020/12/02 06:00
CRDT- 2019/12/19 06:00
PHST- 2019/10/17 00:00 [received]
PHST- 2019/10/18 00:00 [accepted]
PHST- 2019/12/19 06:00 [pubmed]
PHST- 2020/12/02 06:00 [medline]
PHST- 2019/12/19 06:00 [entrez]
AID - 000504241 [pii]
AID - 10.1159/000504241 [doi]
PST - ppublish
SO  - Blood Purif. 2020;49(1-2):197-201. doi: 10.1159/000504241. Epub 2019 Dec 18.